Martin Dyer, MA, Phil, FRCP, FRCpath, from the University of Leicester, Leicester, UK discusses the challenges in developing targeted therapies for patients with double hit lymphoma (DHL). Patients with double hit lymphoma have two chromosomal translocations involving the BCL2 and MYC gene, which results in the suppression of apoptosis by BCL2 and increased proliferation by MYC. Nearly all DHL patients are currently treated with R-CHOP immunochemotherapy, however, the patient outcomes have been poor and it seems that multiple drugs are required to target several different signaling pathways simultaneously. Currently, there is data on effective and successful treatment options, some potential agents like venetoclax look to be promising. This interview was recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
